Several landmark cardiovascular outcome trials have demonstrated that GLP-1RAs can significantly reduce the risk of major adverse cardiovascular events (MACE), which include cardiovascular death, nonfatal myocardial infarction (heart attack), and nonfatal stroke [43]
Its an intriguing idea, but much of this messaging oversimplifies how GLP-1 actually works in the body
Economic impacts of overweight and obesity: current and future estimates for 161 countries
But we are very, quite busy right now
This impending patent cliff is a material headwind for Novo Nordisk, but price reductions will drive a substantial uplift in the volume of patients on injectable semaglutide, through preferential reimbursement (by state or PMI payors) and improved affordability for the self-pay segment
Berberine reduces lipid accumulation in obesity via mediating transcriptional function of PPAR